![]()
| As of Tuesday, November 24th: |
LATEST EARNINGS RESULTS
- AIG Board OKs CEO Pay; Benmosche Agrees to Stay
- Half of Banks' Losses May Still Be Hidden: IMF Head
- Deere Reports Quarterly Net Loss, Revenue Falls
- Tiffany Profit Higher Than Expected; Raises Outlook
- Americans Ditch Planes for Trains this Thanksgiving
- Obama Reiterates Commitment to Boost US-India Ties
- FDIC's Bair Cautions on Risks in Bank Break-Up Plan
- Call Me Crazy: Confessions of a Black Friday Shopper
- Turkey Day 101: How Well Do You Know Your Bird?
- Why You Should Play the Reflation Trade: Stock Picker
- Citi Mortgage Reveals What Treasury Won't
- S&P to Hit 1,200 by Year-End: Chief Investor
- Amended Berkshire Hathaway Filing Indicates No Secret Stock Stakes at End of Q3
- Facebook's Biggest-Ever Holiday Shopping Season
- Facebook's New Dual Class Structure - Slow Steps to an IPO
- 5 Big Bank Stocks Investors Should Consider: Strategists
- Gambling Drunk, Texting to Live And America's On Sale - Your Emails
- Nov. 24: Unusual Volume Leaders
MOST SHARED
- The 'Real' Jobless Rate: 17.5% Of Workers Are Unemployed
- Wednesday's Economic News Crunch Could Tilt Markets
- Obama Reiterates Commitment to Boost US-India Ties
- NBA D-League On The Rise
- Australia Wheat Exporters Face Challenges: GrainCorp
- Japan Export Rebound Eases Fear of New Recession
- Starbucks Eyes China as Next Major Market
- Stifling Anger at Work Can Kill, Survey Finds
- The Social Media Gaming Threat
Merck and Schering-Plough delayed the release of their quarterly financial results so investors could first learn the outcome of a new study of their Vytorin cholesterol fighter, and both drug makers' shares fell on jitters about the impending trial data.
Schering-Plough [SGP
Loading...
()
] dropped more than 7 percent, while Merck [MRK
Loading...
()
] was down 3.5 percent. The companies pushed back their earnings releases to after Monday's stock-market close.
![]() |
CNBC.com |
Merck and Schering-Plough sell Vytorin through a joint venture. It and a related drug called Zetia, with collective global annual sales of more than $4.5 billion, are Schering-Plough's biggest products and among the biggest for Merck.
Results of the Vytorin study, called SEAS, will be presented at a scientific meeting in London. They will come on the heels of data from a failed earlier trial of Vytorin, released in January, that pummeled shares of both companies.
The latest study compares the blockbuster medicine to placebo among patients with aortic stenosis, irregular thickening of the main valve to the aorta that can lead to heart failure. An estimated 2 percent of people over age 65 have the condition.
Both companies had planned to report second-quarter earnings before the market opened on Monday.
The 1,873-patient SEAS study, meant to follow subjects for a minimum of four years, is the largest formal trial ever conducted in patients with aortic stenosis.
It is designed to determine whether aggressive cholesterol lowering can prevent heart attacks and cardiac-related deaths among patients who have the underlying condition although they do not have symptoms.
Vytorin is considered one of the most potent cholesterol fighters on the market, with ability to cut levels of the "bad" LDL variety by as much as 60 percent.
Sales of the pill have suffered this year, and shares of Merck and Schering-Plough have fallen sharply, due to Vytorin's failure to cut plaque in neck arteries in a separate trial called Enhance.
Widespread unfavorable publicity followed the release of the Enhance results in mid-January and recommendations by study researchers that patients first try other cholesterol fighters before opting for Vytorin.
Image At Stake
Analysts have said if the new SEAS trial succeeds, it could help redeem Vytorin in the eyes of doctors and patients. But if it fails, they said, it could further tarnish the medicine.
Vytorin combines Merck's Zocor, or simvastatin, which cuts the body's production of LDL, with the newer Zetia (ezetimibe), which prevents the intestines from absorbing LDL. The combination drug is far more expensive than generically available forms of Zocor.
"If Vytorin is yet again characterized as an expensive agent with low effect, prescriptions could be negatively impacted," Goldman Sachs analyst James Kelly said in a research report on Monday.
Kelly said the study involved a patient population that in the past has failed to benefit from statins, the class of cholesterol drugs that includes Zocor and Pfizer [PFE
Loading...
()
] Lipitor.
Whitehouse Station, New Jersey-based Merck said it was delaying its second-quarter earnings report until after the primary researcher for the SEAS trial, Dr. Terje Pedersen of Ulleval University Hospital in Oslo, Norway, presents clinical trial data from the study.
A spokesman for Kenilworth, New Jersey-based Schering-Plough declined to comment on the nature of Pedersen's update.
Pedersen, in a press release of his own on Monday, said a half dozen European and U.S. scientists would participate in his presentation.
Kelly said the study was likely to result in one of two scenarios: either no significant change in any relevant outcomes measure, or no change in cardiovascular outcomes -- such as heart attacks -- but a change in progression of aortic stenosis.
Schering-Plough shares were down $1.53, or 7.1 percent, at $19.91 in morning New York Stock Exchange trade, while Merck fell $1.33 to $36.35.
- TiVo Reports Quarterly Loss but Matches Forecasts
TiVo announced a quarterly loss that matched analysts' forecasts, but its sales topped expectations.
- Hewlett-Packard Profit Rises, Matches Guidance
Hewlett-Packard said a strong performance in China and improved profit margins in its services business helped drive quarterly earnings 14 percent higher.
- Analog Devices Results Beat Expectations; Shares Rise
Analog Devices reported a quarterly profit that fell from a year ago but topped Wall Street's expectations, sending shares higher in extended trading.
- TiVo Reports Quarterly Loss but Matches Forecasts
- Tyson Food Profit Beats Estimates
Tyson Foods posted higher-than-expected quarterly results on Monday on strength in its beef, pork and prepared foods businesses, which it expects to continue in its new fiscal year.
- Tyson Food Profit Beats Estimates
- Horton Results Miss Estimates, Shares Drop
- Dell Shares Smacked as Earnings, Sales Miss Forecasts
- Gap Reports Earnings in Line With Forecasts
- Intuit Posts Narrower-Than-Expected Loss
- Sears Posts Second Consecutive Quarterly Loss
- BJ's Wholesale Profit Falls, Hurt by Falling Food Prices
- Salesforce Profit Beats Forecasts, but Shares Fall
- Autodesk Shares Fall on Disappointing Outlook
- Home Depot Profit Beats; Says Markets Under Pressure
- Target Third Quarter Profit Up, Cautious on Fourth
- Weak US Housing Market Drags on Lowe's Profit
- JC Penney Profit Falls, but Shares Up on Forecast
- Disney Profit, Sales Top Forecasts; Shares Jump
- Nordstrom Earnings Miss Forecasts; Shares Take Hit
- Wal-Mart Holiday Forecast Light, Profit Beats








